Agree. Continued growth in their LATAM total contact value in radiology and commencing commercial contracts in the new verticals will build the SP steadily.
But - First material commercial contract in a developed market will cause massive rerate I think. As you say, trial/pilot in place already in AU. Newcastle, nice.
I believe you are right, they are able to substantially undercut competitors on price but still command strong margins.
FDA submission/approval will also be a future catalyst.
